[Effect of thymalin on the status of immunogenesis and hemostasis in patients with ischemic heart disease].

Kuznik BI, Budazhabon GB, Sytnikova IA, Morozov VG, Khavinson VKh

Terapevticheskii arkhiv1 Jan 1986

PMID3488603PepBankPUB-03488603

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

1 result from studies that gave the peptide. 1 result from people.

01HumanNon-randomized trialEfficacy outcome
In patients with coronary heart disease, pain disappeared faster with thymalin than in patients who did not receive it.
In plain wordsIn patients with coronary heart disease, pain disappeared faster with thymalin than without it.
Peptide
Thymalin
Outcome
IncreasePain syndrome disappearance
Study
n: not reported in source
Patients with coronary heart disease and effort or rest angina
Comparator
Patients who did not receive thymalin
Outcome group
Pain · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
A more rapid disappearance of the pain syndrome was noted in these patients as compared to those who had not received the drug.
Report a problemFND-0348860308

Studies that did not test the peptide alone7

In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymalin.

02HumanNot a test of Thymalin aloneNon-randomized trialMechanism
In patients with coronary heart disease, multimodality therapy with thymalin normalized cellular immunity.
In plain wordsIn patients with coronary heart disease, multimodality therapy with thymalin normalized cellular immunity.
Peptide
Thymalin
Outcome
Direction not reportedCellular immunity
Study
n: not reported in source
Patients with coronary heart disease and effort or rest angina
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
It was established that the use of thymalin in multimodality therapy of CHD patients suffering from attacks of angina pectoris of effort and at rest brought back to normal the state of cellular and humoral immunity,
In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.
Report a problemFND-0348860301
03HumanNot a test of Thymalin aloneNon-randomized trialMechanism
In patients with coronary heart disease, multimodality therapy with thymalin normalized humoral immunity.
In plain wordsIn patients with coronary heart disease, multimodality therapy with thymalin normalized antibody-related immunity.
Peptide
Thymalin
Outcome
Direction not reportedHumoral immunity
Study
n: not reported in source
Patients with coronary heart disease and effort or rest angina
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
It was established that the use of thymalin in multimodality therapy of CHD patients suffering from attacks of angina pectoris of effort and at rest brought back to normal the state of cellular and humoral immunity,
In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.
Report a problemFND-0348860302
04HumanNot a test of Thymalin aloneNon-randomized trialMechanism
In patients with coronary heart disease, multimodality therapy with thymalin slowed blood coagulation.
In plain wordsIn patients with coronary heart disease, multimodality therapy with thymalin slowed blood clotting.
Peptide
Thymalin
Outcome
DecreaseBlood coagulation
Study
n: not reported in source
Patients with coronary heart disease and effort or rest angina
Outcome group
Bleeding and clotting · Cardiovascular
Source sentences
Summary
slowed down blood coagulation,
In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.
Report a problemFND-0348860303
05HumanNot a test of Thymalin aloneNon-randomized trialMechanism
In patients with coronary heart disease, multimodality therapy with thymalin decreased fibrinogen concentration.
In plain wordsIn patients with coronary heart disease, multimodality therapy with thymalin decreased fibrinogen concentration.
Peptide
Thymalin
Outcome
DecreaseFibrinogen concentration
Study
n: not reported in source
Patients with coronary heart disease and effort or rest angina
Outcome group
Bleeding and clotting · Cardiovascular
Source sentences
Summary
decreased fibrinogen and FDP concentration,
In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.
Report a problemFND-0348860304
06HumanNot a test of Thymalin aloneNon-randomized trialMechanism
In patients with coronary heart disease, multimodality therapy with thymalin decreased FDP concentration.
In plain wordsIn patients with coronary heart disease, multimodality therapy with thymalin decreased fibrin breakdown product concentration.
Peptide
Thymalin
Outcome
DecreaseFDP concentration
Study
n: not reported in source
Patients with coronary heart disease and effort or rest angina
Outcome group
Bleeding and clotting · Cardiovascular
Source sentences
Summary
decreased fibrinogen and FDP concentration,
In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.
Report a problemFND-0348860305
07HumanNot a test of Thymalin aloneNon-randomized trialMechanism
In patients with coronary heart disease, multimodality therapy with thymalin enhanced total euglobulin fibrinolysis.
In plain wordsIn patients with coronary heart disease, multimodality therapy with thymalin increased total euglobulin clot breakdown activity.
Peptide
Thymalin
Outcome
IncreaseTotal euglobulin fibrinolysis
Study
n: not reported in source
Patients with coronary heart disease and effort or rest angina
Outcome group
Bleeding and clotting · Cardiovascular
Source sentences
Summary
enhanced total euglobulin and Hageman-dependent fibrinolysis.
In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.
Report a problemFND-0348860306
08HumanNot a test of Thymalin aloneNon-randomized trialMechanism
In patients with coronary heart disease, multimodality therapy with thymalin enhanced Hageman-dependent fibrinolysis.
In plain wordsIn patients with coronary heart disease, multimodality therapy with thymalin increased Hageman-dependent clot breakdown activity.
Peptide
Thymalin
Outcome
IncreaseHageman-dependent fibrinolysis
Study
n: not reported in source
Patients with coronary heart disease and effort or rest angina
Outcome group
Bleeding and clotting · Cardiovascular
Source sentences
Summary
enhanced total euglobulin and Hageman-dependent fibrinolysis.
In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.
Report a problemFND-0348860307

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.